United States: US-China Trade And Investment: 2014 JCCT Yields Significant Market Access Commitments By China

The 25th US-China Joint Commission on Commerce and Trade (JCCT)—an annual, high-level economic summit1—took place December 16-17, 2014 in Chicago, with US and joint China-US "Fact Sheets" released afterwards listing China's commitments.2 Coming on the heels of several bilateral accords reached during President Obama's November 2014 visit to Beijing, the 2014 JCCT yielded several additional commitments by China that have the potential to further ease market access barriers for a wide range of US companies, including those in the high-tech, pharmaceuticals, medical devices and biotechnology sectors. As always, companies whose business interests are potentially affected should closely monitor China's implementation of these commitments and get involved in preparations for future US-China bilateral summits. 

Outcomes of the 2014 JCCT

US officials cited "dozens" of JCCT outcomes that would enhance US companies' access to China's market.3 Among these are the five categories of outcomes discussed below, pertaining to technology localization requirements, pharmaceuticals and medical devices approvals, trade secrets, the Anti-Monopoly Law (AML), and agricultural biotechnology approvals.

  • Technology Localization Requirements: China has made the receipt of certain tax preferences and other benefits contingent on the transfer of technology to a Chinese company. For example, the High and New Technology Enterprise (HNTE) program offers qualified companies a 15% corporate income tax rate (versus the standard 25% rate), provided they either own IP rights to core technology in China, or provide an exclusive global license for such IP to a Chinese entity for at least five years. In addition, as the Administration has noted, US and other foreign companies operating in China sometimes face pressure to relocate R&D activities to China.
    Through the 2014 JCCT, China committed to "treat intellectual property rights owned or developed in other countries the same as domestically owned or developed intellectual property rights. Enterprises are free to base technology transfer decisions on business and market considerations, and are free to independently negotiate and decide whether and under what circumstances to assign or license intellectual property rights to affiliated or unaffiliated enterprises." This apparently broad market access commitment should go a long way in resolving concerns regarding technology localization requirements although much, as always, will depend on how the commitments are implemented on the ground, and continued vigilance—as well as future action within the JCCT and other bilateral summits, such as the annual US-China Strategic & Economic Dialogue (S&ED)—will be key.
  • Pharmaceuticals and Medical Devices Approvals: China maintains a number of regulatory requirements for pharmaceuticals and medical devices that limit US companies' market access. For example, China's clinical trial approval process typically takes 12-18 months, versus 30-60 days in the United States. In addition, China requires local clinical trials for new pharmaceutical products and variants of existing pharmaceutical products, even though global clinical trial data can provide a sufficient scientific basis to ensure product safety for the Chinese public.
    Through the 2014 JCCT, with respect to pharmaceuticals, China addressed such concerns by committing to: (i) "make great efforts to eliminate the drug application backlog within 2-3 years," (ii) grant clinical trial waivers for companies that use multi-regional clinical trial (MRCT) data that includes data from China, in order to prevent duplicative testing—provided that applications comply with technical review requirements; and (iii) implement measures that allow simultaneous clinical trials in China and other countries.4 In addition, with respect to medical devices, China committed to "expand the scope of medical devices that can be exempted from conducting clinical trials in China."5,6 In principle, these commitments should ease market access barriers for both pharmaceuticals and medical devices. However, it remains unclear to what extent China will reduce the drug application backlog within the stipulated timeframe of 2-3 years, and also whether China will take further steps to embrace the MRCT paradigm. 
  • Trade Secrets: Many US businesses are concerned about the level of protection afforded to trade secrets in China. One particular area of concern is the adequacy of legal safeguards for trade secrets handled by government officials, who often have access to companies' trade secrets and proprietary information in connection with regulatory, administrative and judicial proceedings.
    In the 2014 JCCT, China committed that "trade secrets submitted to the government in administrative or regulatory proceedings are to be protected from improper disclosure to the public and only disclosed to government officials in connection with their official duties in accordance with law." China also agreed to study how to "optimize . . . relevant administrative and regulatory procedures . . . including by strengthening confidentiality protection measures, limiting the scope of government personnel having access to trade secrets, limiting the information required from companies to include only information reasonably necessary for satisfying regulatory purposes, and stipulating that any requirements on government agencies to publicly disclose information appropriately allow for the withholding of trade secrets."7 These commitments present a further development beyond what was agreed to in the July 2014 S&ED. Much, however, will depend on China's actual implementation. 
  • Anti-Monopoly Law: Foreign industry has voiced concern that China's enforcement of the AML—China's first comprehensive competition law—functions as a market access barrier. This is because Anti-Monopoly Enforcement Agency (AMEA) investigations (including both abuse of market dominance investigations and merger reviews)8 arguably focus disproportionately on foreign companies, leading to outcomes that sometimes appear linked to industrial policy objectives such as encouraging the growth and consolidation of domestic industry. In addition, foreign industry has complained that due process deficiencies—e.g., lack of access to counsel and the absence of written penalty decisions for abuse of dominance investigations—aggravate the AML's market-restricting effects. The industries affected by China's enforcement of the AML include high-tech, agriculture, mining, medical devices, pharmaceuticals and automobiles, among others.
    Through the 2014 JCCT, China made several commitments which, in principle, should ease foreign industry concerns:
    • Access to Counsel: China will allow local counsel to participate in meetings with AMEAs without restrictions. In addition, China will allow qualified international counsel to participate subject to approval by the relevant AMEA, "which shall be granted as normal practice."
    • More Transparent Penalty Procedures: China committed that before imposing penalties, AMEAs will "notify the parties of the facts, grounds, and basis according to which the administrative penalties are to be decided, notify the parties of the rights that they enjoy in accordance with the law, and provide the parties with the right to state their cases and to defend themselves." In addition, China committed that all penalty decisions "will be provided in writing to the party and include the facts, reasons, and evidence on which the decision is based." 
    • Competition-Oriented Remedies: China committed that AML remedies would "address the harm to competition" rather than "impose enforcement measures designed to promote individual competitors or industries."
  • Agricultural Biotechnology Approvals: For several years China has delayed, and in some cases denied, approval for certain US genetically modified crop exports. The result is that China's very large market has effectively been closed to a range of US biotech agricultural products.
    Through the 2014 JCCT, China partially addressed these concerns by agreeing to grant three pending approvals of biotechnology products in 2014.10 In addition, China and the United States agreed to conduct an annual Strategic Agricultural Innovation Dialogue, which could pave the way for faster approvals and greater market access. This dialogue has the potential to lead to a comprehensive framework agreement for ensuring timely approvals of all pending applications for US genetically modified crop exports, which the US biotech industry had called for in advance of the JCCT.11 However, it remains to be seen whether and how quickly pending and future applications will be approved.

Other 2014 JCCT commitments by China relate to issues such as geographical indications; inventor remuneration; sale of IP-intensive goods and services; online infringement; government procurement regulations; treatment of IP in standards setting; bad faith patent litigation; illegal, unreported or unregulated fishing; legal services; and a range of cooperative activities.12 The full English-language 2014 JCCT Fact Sheets are available at http://www.commerce.gov/news/fact-sheets/2014/12.
Next Steps
The 2014 JCCT outcome potentially represents a significant step forward in a number of areas that are of key concern to US and other non-Chinese companies in particular. Companies and other stakeholders should actively monitor implementation and, to the extent they may be affected, get involved in preparations for future bilateral summits such as the 2015 S&ED and JCCT to ensure that their concerns are taken on board and placed as high on the bilateral agenda as possible.

1 The 2014 JCCT was co-chaired by US Secretary of Commerce Penny Pritzker, US Trade Representative Michael Froman, and Chinese Vice Premier Wang Yang.
2 The US Fact Sheet was initially released December 18, 2014, and the Joint US-China Fact Sheet was released December 29, 2014. See http://www.commerce.gov/news/fact-sheets/2014/12.
3 Inside U.S. Trade, "U.S. Officials Announce JCCT Progress On AML, GMO Approvals, GIs" (Dec. 18, 2014).
4 In addition, with respect to the supplementation of data submitted for pharmaceutical product patent applications, China and the United States "affirm[ed] that continued exchanges and engagement exchanges and engagement on specific cases are beneficial."
5 The September 2014 Regulations on Supervisory Management of Medical Devices requires clinical trials for all Class II and Class III medical devices unless specifically exempted. This requirement has the potential to significantly restrict medical devices' market access in China. However, China's 2014 JCCT commitments regarding medical devices suggest that China will grant exemptions to mitigate restrictions on market access.
6 In addition, with respect to both pharmaceuticals and medical devices, China committed that "for all draft . . . rules and regulations where notifications are required under the relevant WTO rules, a comment period will be provided that will be no less than 60 days."
7 The 2014 JCCT Fact Sheet also contains the following commitments: "Government officials who illegally disclose companies' trade secrets are to be subject to administrative or legal liability according to law. The United States and China agree to exchange information on the scope of protection of trade secrets and confidential business information under their respective legal systems. China acknowledges that it is to conduct a legislative study of a revised law on trade secrets."
8 Investigations of abuse of market dominance are carried out by the National Development and Reform Commission (NDRC) (in the case of price-based investigations) and the State Administration for Industry and Commerce (SAIC) (in the case of non-price-based investigations), while merger reviews are performed by the Ministry of Commerce (MOFCOM). These are the three Anti-Monopoly Enforcement Agencies (AMEAs). Each AMEA's regional counterparts also participate in AML enforcement.
9 China made a similar commitment at the 2014 S&ED "that the objective of competition policy is to promote consumer welfare and economic efficiency rather than promote individual competitors or industries." US Department of the Treasury, Press Release, "UPDATED: U.S.-China Joint Fact Sheet Sixth Meeting of the Strategic and Economic Dialogue" (July 11, 2014), available athttp://www.treasury.gov/press-center/press-releases/Pages/jl2561.aspx.
10 The products were genetically modified varieties of soybeans and corn. See Inside U.S. Trade, "U.S. Officials Announce JCCT Progress On AML, GMO Approvals, GIs" (Dec. 18, 2014).
11See Letter from U.S. Biotech Crops Alliance to US Trade Representative Michael Froman, US Secretary of Commerce Penny Pritzker, and US Secretary of Agriculture Tom Vilsack (Dec. 10, 2014).
12 The US-China Bilateral Investment Treaty was not cited in the 2014 JCCT, even though it was cited in the 2014 S&ED Joint Fact Sheet http://www.treasury.gov/press-center/press-releases/Pages/jl2561.aspx. The reason for this omission is unclear. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions